CareCloud, Inc. - CCLD STOCK NEWS

CareCloud (Nasdaq: CCLD) announced the continuation of proxy solicitation from Series A Preferred Shareholders to approve an amendment to the Certificate of Designations, Preferences and Rights of its Series A Preferred Stock. As of August 2, 2024, 38% of Series A Preferred Stock shares have returned proxies, with 87% in favor of the Preferred Stock Proposal.

If approved, Series A Preferred Stock holders would receive similar change of control protections as Series B Preferred Stock holders. The proposal also includes aligning the Series A dividend with Series B and granting the Company the right to exchange Series A shares for common stock at $25/share plus accrued dividends.

To pass, the proposal needs approval from 66.67% of outstanding Series A Preferred Stock. Voting is open until August 21, 2024. The Company cautions that future results may differ from current trends.

CareCloud, Inc. (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology and generative AI solutions for medical practices and health systems, has announced it will release its financial results for Q2 2024 on August 13, 2024, before the market opens. The company will host a conference call for investors at 8:30 a.m. Eastern Time on the same day.

Investors can access the live webcast and presentation slides at ir.carecloud.com/events. An audio-only option is available by dialing 201-389-0920. A replay of the call and slides will be available approximately one hour after the call concludes at the same link, with an audio-only replay accessible by dialing 412-317-6671 and using access code 13747693.

CareCloud (Nasdaq: CCLD) announced the continuation of proxy solicitation for its Series A Preferred Stock proposal. With 20% of shares voted, 82% favor the changes, up from 72% last week. The proposal requires approval from two-thirds of outstanding shares (about 3 million of 4.5 million) by August 21, 2024. If approved, Series A holders would receive similar change of control protections as Series B holders, and the dividend would mirror Series B. The company would gain the right to exchange Series A shares for common stock at $25/share plus accrued dividends. Voting can be done by phone, online, or mail. The company cautions that future results may vary and non-votes count as 'no' votes.

CareCloud (CCLD) reports encouraging trends in the voting on its Series A Preferred Stock proposal. 72% of Series A Preferred Shares that have returned proxies to date approve the Preferred Stock Proposal. The company needs an affirmative vote of at least two-thirds of all outstanding Series A Preferred Stock (about 3 million of 4.5 million shares) for the proposal to pass.

If approved, the proposal would grant Series A Preferred Stockholders similar change of control protections as Series B Preferred Stockholders, align the dividend with Series B Preferred Stock, and allow CareCloud to exchange Series A Preferred Stock for common stock at the $25/share liquidation preference value plus accrued dividends. The voting deadline is August 21, 2024.

CareCloud, Inc. (Nasdaq: CCLD) has expanded its partnership with DrFirst to include RxInform functionality, aimed at improving medication adherence and reducing healthcare costs. This integration enhances CareCloud's platform by:

1. Addressing financial challenges through notifications and coupons for patients
2. Offering a seamless notification system for prescription updates
3. Providing text alerts throughout the prescription process
4. Incorporating coupons and discount cards to alleviate financial burdens

The partnership aims to reduce prescription abandonment, improve patient engagement, and ultimately lead to better health outcomes. DrFirst's RxInform has maintained a 95% satisfaction rate based on over 20 million patient ratings.

CareCloud (Nasdaq: CCLD) announced an amendment proposal for its 11% Series A Cumulative Redeemable Perpetual Preferred Stock. The proposal seeks to align the terms of Series A Preferred Stock with those of the 8.75% Series B Preferred Stock. If approved, Series A stockholders would gain change of control protections, a reduced 8.75% dividend rate, and an optional exchange feature. The amendment requires a two-thirds majority approval from Series A shareholders. The Special Meeting is scheduled for August 23, 2024, with proxies being solicited starting July 8, 2024. These changes aim to better position shareholders for potential future transactions and enhance value.

CareCloud announced the results of its 2024 Annual Shareholder Meeting held on June 17, 2024. Shareholders re-elected A. Hadi Chaudhry, John Daly, Mahmud Haq, and Cameron Munter as directors with over 90% approval. Additionally, shareholders approved the compensation for the company's named executive officers as outlined in CareCloud's 2024 Proxy Statement. The meeting's outcomes were filed in a Form 8-K with the SEC. Executive Chairman Mahmud Haq expressed gratitude for the support from shareholders, customers, and employees, and highlighted the company's goals to grow free cash flow, expand AI solutions, and increase the customer base.

CareCloud (Nasdaq: CCLD) announced that CEO Hadi Chaudhry and President Stephen Snyder will discuss the use of generative AI in healthcare. The discussion will take place in a fireside chat on June 4, 2024, during a virtual conference hosted by Maxim Group. CareCloud serves 2,600 physician practices across the U.S., and the leadership will highlight how generative AI can enhance healthcare services and operational efficiencies. The event aims to explore AI's broader impact on the healthcare industry.

CareCloud has promoted Crystal Williams to Chief Operating Officer (COO), effective May 21, 2024. Williams brings over 20 years of experience in revenue cycle management (RCM) and was previously VP of Client Operations at CareCloud. She aims to streamline operations and enhance profitability. Williams' prior roles include leadership positions at GE Healthcare, where she led initiatives to improve efficiencies, margins, and client revenue. This strategic move is intended to leverage CareCloud's global operations for better client experiences and patient outcomes.